



Better Testing, Better Treatment

PDMR Shareholding/Share Incentive Plan

Released : May 11, 2022

RNS Number : 1484L
Diaceutics PLC
11 May 2022

11 May 2022

Diaceutics PLC
("Diaceutics" or "the Company")

PDMR Shareholding/Share Incentive Plan

[Diaceutics PLC](#), (AIM: DXRX), the diagnostic commercialisation company has been notified that on 10 May 2022 Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust purchased ordinary shares ("Shares"), on behalf of Susanne Munksted, a PDMR, in respect of her purchase of Shares pursuant to the Company's Global Share Incentive Plan ("the SIP Scheme") for employees. These purchases will be made each month until further notice.

In accordance with the SIP Scheme, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 2:1.

Enquiries:

Diaceutics PLC

Nick Roberts, Chief Financial Officer

Via Alma PR

Stifel Nicolaus Europe Limited (Nomad & Broker)

Ben Maddison
Stewart Wallace
Nick Adams

Tel: +44 (0)20 7710 7600

Alma PR

Caroline Forde
Kieran Breheny
Matthew Young

Tel: +44(0)20 3405 0205
diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Susanne Munksted

2 Reason for notification												
a.	Position/Status	Chief Precision Medicine Officer and PDMR										
b.	Initial notification/ Amendment	Initial										
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor												
a.	Name	Diaceutics PLC										
b.	LEI	213800VEWQBB39ZB8J81										
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted												
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64										
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP")										
c.	Price(s) and volume(s)	Share purchase: <table border="1" style="margin-left: 40px;"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>1.13 p</td> <td>130</td> </tr> <tr> <td colspan="2">Conditional share award:</td> </tr> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> <tr> <td>Nil</td> <td>260</td> </tr> </tbody> </table>	Price(s)	Volume(s)	1.13 p	130	Conditional share award:		Price(s)	Volume(s)	Nil	260
Price(s)	Volume(s)											
1.13 p	130											
Conditional share award:												
Price(s)	Volume(s)											
Nil	260											
e.	Date of the transaction	Share purchase and Conditional share award: 10 May 2022										
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange Conditional share award: Off-Market										

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBKDBNNBKDNPD